Transdermal Patch With Local Opening For High-Concentration Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing transdermal and transmucosal delivery devices are limited in their ability to provide maximum delivery of dermatological ingredients for local skin conditions, requiring repetitive applications due to the limited amount of active ingredient that can be delivered.
Innovation Solution
A device with a backing layer and a cover having at least one opening, sealed with non-degradable seals, where an adhesive layer adheres the device to the skin without covering the opening, allowing for maximum delivery of ingredients through the opening when the release liner is removed.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a controlled release device is used for transdermal delivery, then the drug is delivered systemically at a controlled rate, but the amount of active ingredient delivered is limited and repetitive applications are required
Solution Approach 1:
The device divides the active ingredient delivery into two pathways: a microporous membrane for controlled systemic delivery and a separate opening for high-concentration local delivery. This segmentation allows the device to simultaneously achieve controlled release and high quantity delivery by directing different amounts of ingredient through different pathways.
Solution Approach 2:
The device creates different delivery characteristics at different locations: the microporous membrane area provides controlled systemic delivery while the opening area provides high-concentration local delivery. This local quality differentiation resolves the contradiction by allowing both controlled rate and high quantity delivery at different sites on the skin.
2Ease of operation
If a plaster is used for local skin conditions, then the active ingredient can be delivered locally, but the amount delivered is limited by the dimensions of the plaster and solubility of the ingredient
Solution Approach 1:
The device changes the concentration parameter of the active ingredient by providing both a controlled release pathway and a high-concentration opening pathway. This allows the device to deliver both low concentrations for systemic effect and high concentrations for local treatment, overcoming the solubility and quantity limitations of traditional plasters.
Solution Approach 2:
The device segments the delivery function into a plaster base for local treatment and a separate opening for high-concentration delivery. This segmentation allows the device to exceed the traditional quantity limits imposed by plaster dimensions and ingredient solubility.
3Reliability
If an adhesive layer covers the entire backing layer, then the device adheres well to the skin, but the opening is covered and ingredient delivery is blocked
Solution Approach 1:
The adhesive layer is applied with local quality differentiation: it covers most of the backing layer for strong adhesion but deliberately excludes the opening area to allow ingredient delivery. This resolves the contradiction by making the adhesive coverage non-uniform, providing both strong attachment and unobstructed delivery pathway.
4Reliability
If a release liner covers the adhesive layer and microporous membrane, then the device is protected during storage, but the opening is covered and ingredient delivery is blocked when applied
Solution Approach 1:
The release liner is designed with local quality differentiation: it covers the adhesive layer and microporous membrane for protection during storage but leaves the opening exposed. This allows the device to maintain protection where needed while ensuring the opening remains accessible for immediate ingredient delivery upon application.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables high-concentration delivery of active ingredients over short periods, overcoming the limitations of existing devices by allowing for increased and controlled release of ingredients directly to the skin, enhancing treatment efficacy for conditions like warts, calluses, and actinic keratoses.
Implementation Method 1
a microporous membrane that is permeable to the ingredients contained in the reservoir
Implementation Method 2
An adhesive layer is adhered to the backing layer
Data Source
AI summary
A dermal, transdermal, mucosal or transmucosal delivery device is provided. The device includes a backing layer, defining an ingredient containing reservoir, a cover for the reservoir having at least one opening therethrough, an adhesive layer and a liner layer. Upon removal of the liner layer, the device may be placed over the desired area of the skin or mucosa and adhesively applied thereto allowing the ingredients to flow from the reservoir through the at least one opening to the dermis or mucosa.